Active

Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials

Switched

BE1013225475

Rechtspersoon Internationale vereniging zonder winstoogmerk

Active for

1 year, 7 months

Registered office

Mijlenmeersstraat 90

1070 Anderlecht

België

Names & denominations

Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials

Official name

FR

Oncodistinct

Commercial name

FR

Enterprise details

Enterprise type

Rechtspersoon

Legal form

Internationale vereniging zonder winstoogmerk

Legal situation

Normale toestand

Start date

5 September 2024

Contact

Not specified

Peppol

Active
0208:1013225475

Active since 19 Mar 2026

Powered by

Databakkes.be

Company info. No nonsense.

Activities

NACE-BEL activity descriptions are currently shown in Dutch. English translations are underway.

NACE-BEL activities

What does this company officially do?

86999 Main activity

Overige activiteiten op het gebied van menselijke gezondheidszorg, neg

What are NACE codes? NACE-BEL is the Belgian version of the European activity nomenclature. Each company has at least one code indicating its main activity.

Establishments

Establishment units

Physical locations of this company

Registered office

Mijlenmeersstraat 90

1070 Anderlecht

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Frequently asked questions

What is the enterprise number of Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials?
The enterprise number of Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials is BE1013225475.
What is the address of Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials?
The registered office of Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials is located at Mijlenmeersstraat 90, 1070 Anderlecht.
When was Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials founded?
Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials was founded on 5 September 2024.
What is the main activity of Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials?
The main activity of Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials is "Overige activiteiten op het gebied van menselijke gezondheidszorg, neg" (NACE code 86999).
Does Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials have a website?
No website is currently known for Oncodistinct Accelerating Oncology drug Development and Innovative strategies in Clinical Trials.